Minerva Neurosciences | NERV - Cost Of Sales


Minerva Neurosciences reported 386K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Adma Biologics USD 33.74M 16.65M Mar/2026
ALKERMES USD 120.7M 47.44M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Cipla INR 29.71B 3.4B Jun/2026
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.82M 1.71M Mar/2026
CSL USD 3.87B 2.08B Dec/2025
Eli Lilly USD 3.27B 309M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
J&J USD 8B 67M Jun/2026
Merck USD 3.14B 200M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.09B 498M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
Takeda JPY 517.6B 42.94B Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024